# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BioNTech reports Q1 loss, missing revenue expectations. Despite challenges, BioNTech aims for significant growth, fueled by inn...
Pfizer analysts from Goldman see a positive outlook on Padcev, Prevnar, and Vindaqel, but Nurtec and Oxbryta execution needs work.
Morgan Stanley analyst Terence Flynn maintains Pfizer (NYSE:PFE) with a Equal-Weight and raises the price target from $28 to...
BMO Capital analyst Evan David Seigerman reiterates Pfizer (NYSE:PFE) with a Outperform and raises the price target from $33...